Literature DB >> 9930862

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

H Walczak1, R E Miller, K Ariail, B Gliniak, T S Griffith, M Kubin, W Chin, J Jones, A Woodward, T Le, C Smith, P Smolak, R G Goodwin, C T Rauch, J C Schuh, D H Lynch.   

Abstract

To evaluate the utility of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic, we created leucine zipper (LZ) forms of human (hu) and murine (mu) TRAIL to promote and stabilize the formation of trimers. Both were biologically active, inducing apoptosis of both human and murine target cells in vitro with similar specific activities. In contrast to the fulminant hepatotoxicity of LZ-huCD95L in vivo, administration of either LZ-huTRAIL or LZ-muTRAIL did not seem toxic to normal tissues of mice. Finally, repeated treatments with LZ-huTRAIL actively suppressed growth of the TRAIL-sensitive human mammary adenocarcinoma cell line MDA-231 in CB.17 (SCID) mice, and histologic examination of tumors from SCID mice treated with LZ-huTRAIL demonstrated clear areas of apoptotic necrosis within 9-12 hours of injection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9930862     DOI: 10.1038/5517

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  641 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Why is apoptosis important to clinicians?

Authors:  C Haslett; J Savill
Journal:  BMJ       Date:  2001-06-23

3.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Authors:  D L Lacey; H L Tan; J Lu; S Kaufman; G Van; W Qiu; A Rattan; S Scully; F Fletcher; T Juan; M Kelley; T L Burgess; W J Boyle; A J Polverino
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2.

Authors:  Rosa Martín-Pérez; Maho Niwa; Abelardo López-Rivas
Journal:  Apoptosis       Date:  2012-04       Impact factor: 4.677

Review 5.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.

Authors:  Vassiliki Poulaki; Constantine S Mitsiades; Vassiliki Kotoula; Sophia Tseleni-Balafouta; Avi Ashkenazi; Demetrios A Koutras; Nicholas Mitsiades
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine.

Authors:  Oscar Antonio Ortega-Rivera; J Luis Quintanar; Susana Del Toro-Arreola; Ángel G Alpuche-Solis; Mayra J Esparza-Araiza; Eva Salinas
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

8.  Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL.

Authors:  Qiuwei Pan; Bisheng Liu; Jin Liu; Rong Cai; Yigang Wang; Cheng Qian
Journal:  Mol Cell Biochem       Date:  2007-06-19       Impact factor: 3.396

9.  Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame.

Authors:  Weiliang Tang; Catherine A Lázaro; Jean S Campbell; W Tony Parks; Michael G Katze; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

Review 10.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.